- Home
- ETV vs BEAM Comparison
ETV vs BEAM Comparison
Compare ETV & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETV
- BEAM
- Stock Information
- Founded
- ETV 2005
- BEAM 2017
- Country
- ETV United States
- BEAM United States
- Employees
- ETV N/A
- BEAM N/A
- Industry
- ETV Investment Managers
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ETV Finance
- BEAM Health Care
- Exchange
- ETV Nasdaq
- BEAM Nasdaq
- Market Cap
- ETV 1.6B
- BEAM 1.6B
- IPO Year
- ETV N/A
- BEAM 2020
- Fundamental
- Price
- ETV $13.39
- BEAM $16.76
- Analyst Decision
- ETV
- BEAM Strong Buy
- Analyst Count
- ETV 0
- BEAM 11
- Target Price
- ETV N/A
- BEAM $48.90
- AVG Volume (30 Days)
- ETV 252.5K
- BEAM 1.8M
- Earning Date
- ETV 01-01-0001
- BEAM 08-05-2025
- Dividend Yield
- ETV 8.75%
- BEAM N/A
- EPS Growth
- ETV N/A
- BEAM N/A
- EPS
- ETV N/A
- BEAM N/A
- Revenue
- ETV N/A
- BEAM $63,578,000.00
- Revenue This Year
- ETV N/A
- BEAM N/A
- Revenue Next Year
- ETV N/A
- BEAM $8.82
- P/E Ratio
- ETV N/A
- BEAM N/A
- Revenue Growth
- ETV N/A
- BEAM N/A
- 52 Week Low
- ETV $11.05
- BEAM $13.53
- 52 Week High
- ETV $13.50
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- ETV 49.38
- BEAM 44.29
- Support Level
- ETV $13.45
- BEAM $16.18
- Resistance Level
- ETV $13.64
- BEAM $18.33
- Average True Range (ATR)
- ETV 0.13
- BEAM 1.10
- MACD
- ETV -0.04
- BEAM 0.00
- Stochastic Oscillator
- ETV 11.29
- BEAM 28.65
About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in a diversified portfolio of common stocks, designated segments of which seek to exceed the total return performance of the S&P 500 and the NASDAQ-100.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.